Evidence map›Paper›PMID 36083488›Full record

Trial reportJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2022

Wenshen Jianpi recipe induced immune reconstruction and redistribution of natural killer cell subsets in immunological non-responders of human immunodeficiency virus/acquired immune deficiency syndrome: a randomized controlled trial.

Tao Zhuang, Wang Jian, Chen Xin, L I Yonghong, Yan Yuguang, Zhang Ao, Zou Wen, Liu Ying

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tao ZhuangResearch Center of AIDS Treatment with Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Wang JianResearch Center of AIDS Treatment with Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Chen XinDepartment of Integrated Traditional Chinese and Wetern Medicine, Kunming Hospital of Traditional Chinese Medicine, Kunming 650000, China.
L I YonghongDepartment of Infection, No.6 People's Hospital of Shenyang City, Shenyang 110006, China.
Yan YuguangDepartment of Infection, No.6 People's Hospital of Shenyang City, Shenyang 110006, China.
Zhang AoUniversity of Chinese Academy of SoCIal SCIences, Beijing, 100102, China.
Zou WenResearch Center of AIDS Treatment with Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Liu YingResearch Center of AIDS Treatment with Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effects of the Wenshen Jianpi recipe (, WJR) on immune reconstruction and natural killer (NK) cells in immunological non-responders (INRs) of people living with human immunodeficiency virus (HIV) (PLWH) and propose new therapeutic strategies for HIV.

methodsBased on Traditional Chinese Medicine treatment principle "invigorating and warming in the spleen and kidneys", WJR combined with antire-troviral therapy (ART) therapy was performed in a randomized, double-blind, placebo-controlled study of 60 patients with non-responders. The randomized process was executed by the Clinical Evaluation Center of China Academy of Chinese Medical Sciences. Sixty patients who met the inclusion criteria obtained random numbers (that is the drug number) was randomly divided into a treatment group and a placebo control group according to a 1∶1 ratio. CD4+T cell counts and natural killer (NK) cells counts were evaluated at baseline and 12-week, 24-week follow-ups.

resultsFour participants received random numbers and did not enter the group due to the patient's own reasons. A total of 56 patients were enrolled, including 28 in the treatment group and 28 in the control group. CD4+T cell counts in the treatment group were significantly increased at week 24 ( = 0.01 < 0.05), which were significantly higher than those in the control group (= 0.01 < 0.05). Although no significant differences were observed between two groups, the CD56briCD16- NK cell counts in the treatment group were significantly increased after duration. and CD56dimCD16+ NK cell counts in the treatment group were significantly higher than those in the control group after 24 weeks of treatment (= 0.025 < 0.05). As compared with the control group, the treatment group had significantly lower CD56negCD16+ NK cell counts after 24 weeks of treatment (= 0.023 < 0.05).

conclusionsWJR promotes the immune reconstruction of INRs and redistribution of NK cell subsets, notably decreasing CD56negCD16+ NK cell counts in INRs. However, the redistribution of NK cell subsets is not beneficial for immune reconstruction in INRs. Further large-scale RCTs are required to evaluate the effect of WJR on immune recovery in INRs and decipher the underlying mechanism.

Indexed as

Acquired Immunodeficiency SyndromeHIV InfectionsCD4 Lymphocyte CountHIVHumansKiller Cells, Naturalacquired immunodeficiency syndromeantiretroviral therapyHIVimmune reconstructionimmunological non-responderskiller cellsnaturalrandomized controlled trialWenshen Jianpi recipe

Identifiers

PMID36083488
PMCPMC9924785
OpenAlexW4295078660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.